GlobeNewsWire
06 Mar 2026, 13:30 UTC · 33w ago
Impact · against what's priced in
Day One Biopharmaceuticals (DAWN) is being acquired by Servier for $21.50 per share in cash. This represents a substantial 68% premium over its last closing price, providing an immediate and material valuation uplift.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash.
More positive than 99% of claims this week
The offer price of $21.50 represents a 68% premium over Day One's closing price on March 5, 2026.
Continue reading
5 related stories
The agreement for Servier to acquire Day One at $21.50 per share represents a 68% premium over the March 5 closing price.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 99% of claims this week
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and U.S. antitrust clearance.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company is being acquired at a significant premium of 68% over its closing price.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
WSJ
4h ago
+68.5%
Price agrees with the score
$21.53 vs $12.78 close before publication (Mar 5) · not market-adjusted
DAWN chart →
